{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:30:22Z","timestamp":1749238222804},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/maj.0b013e3182254bd6","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T12:17:06Z","timestamp":1312460226000},"page":"316-319","source":"Crossref","is-referenced-by-count":9,"title":["What Would We Do Without Metronidazole?"],"prefix":"10.1016","volume":"343","author":[{"given":"Kayla R.","family":"Stover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Riche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie L.","family":"Gandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0005","first-page":"419","article-title":"Metronidazole","volume":"Vol. 1","author":"Salvatore","year":"2010"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3182254bd6_bb0010","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","article-title":"Metronidazole: a therapeutic review and update","volume":"54","author":"Freeman","year":"1997","journal-title":"Drugs"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1540-8159.2005.09348.x","article-title":"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone","volume":"28","author":"Kounas","year":"2005","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0025","series-title":"Clinical drug data","first-page":"279","article-title":"Micellaneous antimicrobials: metronidazole","author":"Gauthier-Lewis","year":"2010"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0030","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.clinthera.2005.12.012","article-title":"Tinidazole: a nitroimidazole antiprotozoal agent","volume":"27","author":"Fung","year":"2005","journal-title":"Clin Ther"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0035","series-title":"San Antonio (TX","article-title":"prescribing information","year":"2007"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14787210.4.1.125","article-title":"Trichomoniasis and its treatment","volume":"4","author":"Nanda","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"suppl 3","key":"10.1097\/MAJ.0b013e3182254bd6_bb0045","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/511425","article-title":"Trichomoniasis: challenges to appropriate management","volume":"44","author":"Wendell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0050","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1086\/522532","article-title":"The prevalence ofTrichomonas vaginalisinfection among reproductive-age women in the United States, 2001\u20132004","volume":"45","author":"Sutton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/AAC.40.5.1121","article-title":"In vitro effect of tinidazole and furazolidone on metronidazole-resistantTrichomonas vaginalis","volume":"40","author":"Narcisi","year":"1996","journal-title":"Antimicrob Ag Chemther"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1071\/SH09064","article-title":"Treatment of metronidazole-resistantTrichomonas vaginalis","volume":"6","author":"Goldman","year":"2009","journal-title":"Sex Health"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1258\/095646204773557848","article-title":"Symptomatic trichomoniasis, metronidazole allergic and pregnant\u2014a management dilemma","volume":"15","author":"Lomax","year":"2004","journal-title":"Int J STD AIDS"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0075","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1258\/0956462054308422","article-title":"Management of metronidazole-resistantTrichomonas vaginalis\u2014a new approach","volume":"16","author":"Mammen-Tobin","year":"2005","journal-title":"Int J STD AIDS"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0080","series-title":"Harrison\u2019s principles of internal medicine","first-page":"1311","article-title":"Protozoal intestinal infections and trichomoniasis","author":"Weller","year":"2008"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0085","first-page":"954","article-title":"Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9","volume":"78","author":"Livengood","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0090","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1067\/mob.2000.105388","article-title":"A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis","volume":"182","author":"Antonelli","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0095","unstructured":"Humatin\u00ae (paromomycin) [prescribing information]. Bristol (TN): Monarch Pharmaceuticals Inc, 2001."},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/323034","article-title":"Tinidazole therapy for metornidazole-resistant vaginal trichomoniasis","volume":"33","author":"Sobel","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/OLQ.0b013e318074e565","article-title":"The prevalence of bacterial vaginosis in the United States, 2001\u20132004; associations with symptoms, sexual behaviors, and reproductive health","volume":"34","author":"Koumans","year":"2007","journal-title":"Sex Transm Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0110","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1089\/jwh.2008.1088","article-title":"Treatment considerations for bacterial vaginosis and the risk of recurrence","volume":"18","author":"Chen","year":"2009","journal-title":"J Womens Health"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0115","series-title":"CDC Division of Parasitic Diseases","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.14.1.114-128.2001","article-title":"Treatment of giardiasis","volume":"14","author":"Gardner","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0125","first-page":"273","article-title":"The old and new therapeutic approaches to the treatment of giardiasis: where are we?","volume":"3","author":"Busatti","year":"2009","journal-title":"Biologics"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.exppara.2009.07.005","article-title":"Cryptosporidium and giardia: treatment options and prospects for new drugs","volume":"124","author":"Rossignol","year":"2010","journal-title":"Exp Parasitol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11938-005-0047-3","article-title":"Treatment of giardiasis","volume":"8","author":"Petri","year":"2005","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0140","series-title":"CDC Division of Parasitic Diseases","author":"Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0145","series-title":"Harrison\u2019s principles of internal medicine","first-page":"1275","article-title":"Amebiasis and infection with free-living amebas","author":"Reed","year":"2008"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0150","article-title":"CDC Health Information for International Travel","author":"Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0155","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4065\/83.10.1154","article-title":"Amebiasis","volume":"83","author":"Pritt","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11894-007-0054-8","article-title":"Amebic colitis: new insights into pathogenesis and treatment","volume":"9","author":"Bercu","year":"2007","journal-title":"Curr Gasterenterol Rep"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0889-8553(05)70259-4","article-title":"Protozoa","volume":"25","author":"Li","year":"1996","journal-title":"Amebiasis. Gastroenterol Clin North Am"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0170","first-page":"16","article-title":"Amoebic liver abscess and clinical experiences with tinidazole in Bangladesh","volume":"81","author":"Quaderi","year":"1978","journal-title":"J Trop Med Hyg"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0175","first-page":"253","article-title":"Low dose tinidazole in the treatment of amoebic liver abscess","volume":"16","author":"Vanijanonta","year":"1985","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0180","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.trstmh.2007.04.001","article-title":"Nitazoxanide in the treatment of amoebiasis","volume":"101","author":"Rossignol","year":"2007","journal-title":"Trans R Soc TropMed Hyg"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0185","unstructured":"Aralen\u00ae (chloroquine phosphate) [prescribing information]. Bridgewater (NJ): Sanofi-aventis U.S. LLC.; 2008."},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0190","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MAJ.0b013e3181e939d8","article-title":"Clostridium difficileinfection","volume":"340","author":"Heinlen","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","article-title":"The changing epidemiology ofClostridium difficileinfections","volume":"23","author":"Freeman","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0200","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3201\/eid1309.061116","article-title":"Increase inClostridium difficile-relatedmortality rates, United States, 1999\u20132004","volume":"13","author":"Redelings","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2307\/30141083","article-title":"Clostridium difficile-associated diarrhea and colitis","volume":"16","author":"Gerding","year":"1995","journal-title":"Infect Cont Hosp Epi"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines forClostridium difficileinfection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0215","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin inClostridium difficileinfection: a randomized, doubleblind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0220","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1345\/aph.1H340","article-title":"Emerging therapies in the treatment ofClostridium difficile-associateddisease","volume":"40","author":"Jodlowski","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0225","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1345\/aph.1K675","article-title":"Rifamycin antibiotics for treatment ofClostridium difficile-associated diarrhea","volume":"42","author":"Garey","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3182254bd6_bb0230","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14656566.2010.485614","article-title":"Fidaxomicin (OPT-80) for the treatment ofClostridium difficileinfection","volume":"11","author":"Miller","year":"2010","journal-title":"Expert Opin Pharmacother"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T15:37:30Z","timestamp":1560440250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915309964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0002962915309964"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182254bd6","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}